Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials

References

• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 Jan;33(Suppl 1):S62–9. doi: 10.2337/dc10-S062
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and diagnosis of diabetes: standards of medical Care in diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S15–S33. doi: 10.2337/dc21-S002
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabet Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020 Mar;10(1):107–111. doi: 10.2991/jegh.k.191028.001
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of Care in diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S140–S157. doi: 10.2337/dc23-S009
   PubMedGoogle Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669–2701. doi: 10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Shubrook JH, Radin M, Ali SN, et al. Preference for type 2 diabetes therapies in the United States: a discrete choice experiment. Adv Ther. 2022 Sep;39(9):4114–4130. doi: 10.1007/s12325-022-02181-7
   PubMed Web of Science ®Google Scholar
• Hallakou-Bozec S, Vial G, Kergoat M, et al. Mechanism of action of imeglimin: a novel therapeutic agent for type 2 diabetes. Diab Obes Metab. 2021 Mar;23(3):664–673. doi: 10.1111/dom.14277
   PubMed Web of Science ®Google Scholar
• Nowak M, Grzeszczak W. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes. Endokrynol Pol. 2022;73(2):361–370. doi: 10.5603/EP.a2022.0014
   PubMed Web of Science ®Google Scholar
• Pacini G, Mari A, Fouqueray P, et al. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diab Obes Metab. 2015 Jun;17(6):541–545. doi: 10.1111/dom.12452
   PubMed Web of Science ®Google Scholar
• Dubourg J, Fouqueray P, Thang C, et al. Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes (TIMES 1): a double-blind, randomized, placebo-controlled, parallel-group, multicenter Phase 3 trial. Diabetes Care. 2021 Apr;44(4):952–959. doi: 10.2337/dc20-0763
   PubMed Web of Science ®Google Scholar
• Reilhac C, Dubourg J, Thang C, et al. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): a randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diab Obes Metab. 2022 May;24(5):838–848. doi: 10.1111/dom.14642
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71
   PubMedGoogle Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated Feb 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898
   PubMedGoogle Scholar
• Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018 Jun;27(6):1785–1805. doi: 10.1177/0962280216669183
   PubMed Web of Science ®Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014 Dec 19;14(1):135. doi: 10.1186/1471-2288-14-135
   PubMedGoogle Scholar
• Dubourg J, Ueki K, Grouin JM, et al. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Diab Obes Metab. 2021 Mar;23(3):800–810. doi: 10.1111/dom.14285
   PubMed Web of Science ®Google Scholar
• Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diab Obes Metab. 2012 Sep;14(9):852–858. doi: 10.1111/j.1463-1326.2012.01611.x
   PubMed Web of Science ®Google Scholar
• Fouqueray P, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565–568. doi: 10.2337/dc12-0453
   PubMed Web of Science ®Google Scholar
• Fouqueray P, Pirags V, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care. 2014 Jul;37(7):1924–1930. doi: 10.2337/dc13-2349
   PubMed Web of Science ®Google Scholar
• Theurey P, Thang C, Pirags V, et al. Phase 2 trial with imeglimin in patients with type 2 diabetes indicates effects on insulin secretion and sensitivity. Endocrinol Diabetes Metab. 2022 Nov;5(6):e371. doi: 10.1002/edm2.371
   PubMedGoogle Scholar
• Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000 Feb;53(2):207–16. doi: 10.1016/s0895-4356(99)00161-4
   PubMed Web of Science ®Google Scholar
• Terrin N, Schmid CH, Lau J, et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med. 2003 Jul 15;22(13):2113–2126. doi: 10.1002/sim.1461
   PubMed Web of Science ®Google Scholar
• Crabtree TS, DeFronzo RA, Ryder REJ, et al. Imeglimin, a novel, first in class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence. Br J Diabetes. 2020;20(1):28–31. doi: 10.15277/bjd.2020.247
   Web of Science ®Google Scholar